Julia Owens: A Deep Dive Into Stroke Care and Basking Bio’s Innovative Programs
Julia Owens, Chief Executive Officer at Basking Biosciences Inc, reposted from Basking Biosciences, Inc. on LinkedIn:
”I have long admired Josh Schimmer‘s biotech insights and wit, so I was thrilled when he wanted to learn more about our work at Basking Bio.
I hope you will listen to this webinar where Josh and Alexa dig into the background of stroke care and our innovative programs with their usual probing questions.”
Quoting Basking Biosciences, Inc.‘s post:
”We had the privilege of joining Josh Schimmer and Alexa Deemer Conzola at Cantor Fitzgerald for a deep dive into acute ischemic stroke and the science behind our lead program, BB-031.
In the recording below, our CEO, Julia Owens, and Co-founder and Chief Scientific Officer, Dr. Shahid Nimjee, walk through the stroke treatment landscape, why targeting von Willebrand Factor represents a fundamentally different approach, and where BB-031 stands in its clinical development.
Thank you, Josh and the Cantor team, for the opportunity to share our story with your audience.
Stay updated with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering